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Background
AIDS-KS remains a significant cause of morbidity and
mortality especially in sub-Saharan Africa in the face of
ART scale-up. We compare survival over a four-year period
between HIV-infected men and women with untreated
AIDS-KS receiving care in Jos, Nigeria.
Patients and methods
The Jos University Teaching Hospital HIV cohort has
more than 10,500 adult patients enrolled for care. We
prospectively collect routine data on individuals, and dur-
ing the study 175 patients presenting with AIDS-KS were
followed up. We compared survival, clinical, immuno-
logic and virologic characteristics between male and
female patients receiving HAART (two NRTIs and one
NNRTI). Comparison of variables between groups was by
χ2 test for nominal variables. Survival was calculated from
the day of enrollment until death or the date of last fol-
low-up using Kaplan-Meier method (Figure 1).
Results
One hundred and three (58.8%) were females while 72
(41.2%) were males, giving a male: female ratio of 1:1.6.
The mean age was 35 ± 7 and 40 ± 7 for females and males
respectively (p < 0.001). Median CD4 count was 105 and
114 cells/mm3 (p, 0.76) while HIV RNA was 43,113 and
80,310 (p, 0.01) median copies/ml for females and males
respectively at baseline. Mean duration of observation was
similar for both sexes (2.3 ± 0.9 years) with 18.4% of
females and 13.9% of males having history of use of
HAART. Seventy-five percent (75%) of the females and 80
percent of the males had disseminated cutaneous disease
and more than 40 percent of the male had nodular lesions
compared with 25.5 percent of the females. The probabil-
ity of survival was similar for both sexes.
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Kaplan-Meier plot for HIV+ patients with untreated AIDS-KS in Jos, Nigeria stratified by sex.Figure 1
Kaplan-Meier plot for HIV+ patients with untreated 
AIDS-KS in Jos, Nigeria stratified by sex.Page 1 of 2
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Despite the availability of HAART, AIDS-KS continues to
significantly affect morbidity and mortality in HIV-
infected patients in our setting. Provision of specific treat-
ment for AKS may improve overall outcome.Page 2 of 2
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